Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome-Reference-Cited by-同舟云学术

Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome

Published:2020-04-10 Issue:4 Volume:15 Page:e0231427
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Fuchigami Akira,Imai Yukinori,Uchida Yoshihito,Uchiya Hiroshi,Fujii Yohei,Nakazawa Manabu,Ando Satsuki,Sugawara Kayoko,Nakayama Nobuaki,Tomiya Tomoaki,Mochida Satoshi

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;J Ferlay;Int J Cancer,2015

2. EASL clinical practice guidelines: management of hepatocellular carcinoma;European Association for the Study of the Liver;J Hepatol,2018

3. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan;M Kudo;Liver Cancer,2014

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial;M Kudo;Lancet,2018

5. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma;R Lencioni;Semin Liver Dis,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study;Hepatology Research;2024-07-02

2. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma;PLOS ONE;2024-04-30

3. Field evaluation of a novel semi-quantitative point-of-care diagnostic for G6PD deficiency in Indonesia;PLOS ONE;2024-04-30

4. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma;Cancer Reports;2024-04

5. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab;Liver International;2024-03-15